The full form of PLD in pharma, based on the provided reference, is pegylated liposomal doxorubicin.
Pegylated liposomal doxorubicin is a chemotherapeutic agent used in the treatment of various cancers, including metastatic breast cancer. Let's break down what each part of this name means:
-
Pegylated: This refers to the process of attaching polyethylene glycol (PEG) to the doxorubicin. Pegylation increases the drug's circulation time in the body by reducing its rate of degradation and recognition by the immune system.
-
Liposomal: This indicates that the doxorubicin is encapsulated within liposomes. Liposomes are spherical vesicles composed of a lipid bilayer. Encapsulation within liposomes helps to protect the drug, improves its delivery to the tumor site, and reduces side effects.
-
Doxorubicin: This is the active chemotherapeutic drug itself, an anthracycline antibiotic that interferes with DNA replication and cell division, ultimately leading to cancer cell death.
In summary, pegylated liposomal doxorubicin (PLD) is a formulation of doxorubicin designed for improved efficacy and reduced toxicity through pegylation and liposomal encapsulation. It's a targeted drug delivery system for cancer treatment.
